Market Place
Sourcing Support
Gilead, US government resolve long-running HIV patent dispute
17 Jan 2025 //
PRESS RELEASE
Gilead, LEO Pharma to programs for inflammatory diseases
13 Jan 2025 //
REUTERS
Gilead Sciences to Present at Upcoming Investor Conference
20 Dec 2024 //
BUSINESSWIRE
Merck`s HIV combo treatment meets efficacy bar in Ph 3 trials
20 Dec 2024 //
FIERCE BIOTECH
Gilead & Terray Announce Multi-Target Research Collaboration
17 Dec 2024 //
BUSINESSWIRE
AI-powered Terray is teaming up with Gilead in a fresh R&D pact
17 Dec 2024 //
FIERCE BIOTECH
Gilead`s Seladelpar Receives CHMP Nod For Biliary Cholangitis
13 Dec 2024 //
BUSINESSWIRE
Gilead appoints Sanofi official Dietmar as next CMO
13 Dec 2024 //
REUTERS
ICER calls out drugmakers over `unsupported` price hikes
12 Dec 2024 //
REUTERS
Gilead spotlights lenacapivir in plan to hold on to HIV crown
11 Dec 2024 //
FIERCE PHARMA
Kite’s Tecartus CAR T Therapy Shows Durable Efficacy at ASH 2024
09 Dec 2024 //
BUSINESSWIRE
Kite`s Yescarta® Shows Durable Response in Relapsed Lymphomas
09 Dec 2024 //
BUSINESSWIRE
Kite`s Yescarta® Highlights Curative Potential in Relapsed Lymphoma
08 Dec 2024 //
BUSINESSWIRE
Gilead taps Tubulis for solid tumor ADC development worth up to $465M
04 Dec 2024 //
PRESS RELEASE
Gilead Announces NEJM Publication of PURPOSE 2 Results
27 Nov 2024 //
BUSINESSWIRE
Designing Inclusive Trials in an Effort To Upend the HIV Epidemic
26 Nov 2024 //
ACCESSWIRE
Gilead buys HIV vaccine from biotech following clinical collab
26 Nov 2024 //
FIERCE BIOTECH
Gilead supports ‘sanctuary’ for Black breast cancer patients
20 Nov 2024 //
FIERCE PHARMA
Ideaya hires Gilead leader to head up commercialization push
19 Nov 2024 //
FIERCE PHARMA
Gilead cuts 100+ positions at California HQ
18 Nov 2024 //
FIERCE PHARMA
Gilead’s Livdelzi Shows Sustained Efficacy in Biliary Cholangitis
15 Nov 2024 //
BUSINESSWIRE
Gilead to lay off 72 staffers, shutter Seattle R&D office
14 Nov 2024 //
FIERCE BIOTECH
Gilead Presents PURPOSE 2 Data on Lenacapavir for HIV Prevention
13 Nov 2024 //
BUSINESSWIRE
Gilead Prices $3.5 Billion of Senior Unsecured Notes
13 Nov 2024 //
BUSINESSWIRE
Gilead Presents Research on Broad HIV Treatment Portfolio
12 Nov 2024 //
BUSINESSWIRE
Gilead`s CAR-T sales stagnate as Trodelvy takes another write-off
11 Nov 2024 //
FIERCE PHARMA
Novo, Lilly lost value in Q3 while BMS, Gilead and Sanofi surged
11 Nov 2024 //
FIERCE PHARMA
Gilead Sciences to Present at Upcoming Investor Engagements
08 Nov 2024 //
BUSINESSWIRE
Gilead Presents Data & Extends HIV Leadership at HIV Glasgow
07 Nov 2024 //
BUSINESSWIRE
Gilead Q3 results beat Wall Street estimates, raises outlook
07 Nov 2024 //
REUTERS
Gilead Sciences Announces Q3 2024 Financial Results
06 Nov 2024 //
BUSINESSWIRE
Kite to Present CAR T-Cell Therapy Data at ASH 2024
05 Nov 2024 //
BUSINESSWIRE
ASH: Gilead-Arcellx data build CAR-T`s case in advanced myeloma
05 Nov 2024 //
FIERCE BIOTECH
Gilead Oncology Grant Supports 22 U.S. Breast Cancer Organizations
31 Oct 2024 //
ACCESSWIRE
Gilead To Present Research At AASLD Meeting 2024
22 Oct 2024 //
BUSINESSWIRE
Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks
22 Oct 2024 //
FIERCE BIOTECH
Gilead withdraws bladder cancer drug in US after failed trial
19 Oct 2024 //
REUTERS
GSK bolsters case for long-acting HIV PrEP drug Apretude
16 Oct 2024 //
FIERCE PHARMA
Gilead gives up on $15M MASH bet after mulling preclinical data
11 Oct 2024 //
FIERCE BIOTECH
Gilead To Present Late-Breaking Data At IDWeek 2024
09 Oct 2024 //
BUSINESSWIRE
Gilead To Release Q3 2024 Results November 6
09 Oct 2024 //
BUSINESSWIRE
Enforcement Report - Week of October 9, 2024
09 Oct 2024 //
FDA
Gilead: Report Shows Countries Must Do More To End HIV Epidemic
08 Oct 2024 //
ACCESSWIRE
Gilead Presents Data From PURPOSE 2 Trial At HIV Conference
07 Oct 2024 //
BUSINESSWIRE
Emcure Pharma partners with Gilead Sciences to produce HIV drug
04 Oct 2024 //
PRESS RELEASE
Gilead To Donate Remdesivir For Emergency Use Against Marburg
03 Oct 2024 //
REUTERS
Dr Reddy`s sign voluntary licenses with Gilead for HIV drug
02 Oct 2024 //
PRESS RELEASE
Gilead inks licensing deals to boost lenacapivir access
02 Oct 2024 //
FIERCE PHARMA
Gilead recalls 1 lot of Veklury due to glass particle in vial
26 Sep 2024 //
FIERCE PHARMA
Gilead leads Asian patient groups’ drugmaker reputation rankings
25 Sep 2024 //
FIERCE PHARMA
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
24 Sep 2024 //
GLOBENEWSWIRE
Gilead Issues Voluntary Nationwide Recall of One Lot of Veklury
23 Sep 2024 //
FDA
Gilead Taps Yuhan To Supply HIV Drug Ingredients In $81M Deal
20 Sep 2024 //
FIERCE PHARMA
Gilead`s Kite Exits China Joint Venture With Fosun
19 Sep 2024 //
FIERCE PHARMA
Gilead`s Long-Acting PrEP Drug Wins Phase 3 Trial, Eyes 2025 Launch
13 Sep 2024 //
FIERCE PHARMA
Helping End HIV - Gilead Sciences
12 Sep 2024 //
ACCESSWIRE
Gilead`s Lenacapavir Shows 96% HIV Infection Reduction In Phase 3
12 Sep 2024 //
BUSINESSWIRE
OmRx Oncology Launches To Advance Oral Checkpoint Inhibitor
12 Sep 2024 //
BUSINESSWIRE
Seramount Ranks Gilead In Leading Inclusion Index Company
10 Sep 2024 //
ACCESSWIRE
Gilead And Genesis Announce Therapeutic Collaboration
10 Sep 2024 //
BUSINESSWIRE
